Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gemin X Pharmaceuticals
Gemin X Initiates Phase 2 Clinical Study of Obatoclax in Combination with Standard Chemotherapy for First-Line Treatment of Small Cell Lung Cancer
March 17th, 2009
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, announced the initiation of a Phase 2 clinical trial of its lead product candidate obatoclax (GX15-070) for the treatment of patients with extensive-stage small cell lung cancer (SCLC). In this multi-center, randomized, open-label Phase 2 study, clinical effect of a combination of carboplatin, etoposide and obatoclax (the “CEO” regimen) will be compared to the standard chemotherapeutic therapy of carboplatin and etoposide alone (the control arm) in patients with SCLC. The primary endpoint of the study, expected to enroll approximately 150 patients with SCLC, is comparison of...
Source: Cancer Weekly (2009-03-17)
|
